{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-035135","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.030318+00:00","generated_at":"2026-05-18T05:59:32.305046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20","bullets":["GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.","Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.","Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.","Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.","Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-035135","json":"https://secwatch.observer/filing/0001628280-25-035135.json","markdown":"https://secwatch.observer/filing/0001628280-25-035135.md","text":"https://secwatch.observer/filing/0001628280-25-035135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/0001628280-25-035135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828025035135/abt-20250717.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:59:32.305046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}